Biomeditsina va amaliyot jurnali, 2022 №1

Maqola mavzusi

EFFECT OF CARDIOPROTECTORS ON QUALITY OF LIFE OF PATIENTS WITH ISCHEMIC HEART DISEASE COMPLICATED WITH CHRONIC HEART FAILURE (335-339)

Mualliflar

KOBILOVA Nigina Akmalovna DJABBAROVA Nafisa Mamasoliyevna

Muassasa

Samarkand State Medical Institute

Annotatsiya

Objective: Evaluate the effect of trimetazidine on the quality of life of patients with coronary artery disease who have had myocardial infarction with chronic heart failure. Methods:We examined 53 patients with coronary artery disease who underwent myocardial infarction [men - 36 (67.9%), women - 17 (32.1%)]. The average age was 63.4 ± 1.3 years. All patients underwent examination: interview and examination; general clinical and biochemical studies, ECG. Assessment of the manifestations of CHF in patients of both groups was carried out according to the New York classification according to the results of the 6-minute walk test. The assessment of the quality of life of patients in points was carried out according to the adapted Minnesota questionnaire (LWHF index: 0 points for excellent quality of life. 100 points for the worst quality of life) of patients with CHF. Results: On the background of the treatment, the quality of life of the patients improved. This was reflected in the positive dynamics in the distribution of patients according to FC and the assessment of the occurrence of CHF, there was a positive trend: in the group taking predizin - the number of patients with FC II and FC I CHF increased compared to the initial data, the number of patients with FC III and FC IV CHF decreased, and in the control group there was a slight negative dynamics. Conclusions.There was a significant difference and a better treatment effect in the control group. Thus, the addition of predizin to the complex therapy leads to a more pronounced improvement in the general condition of patients and the normalization of echocardiography.

Kalit so'zlar

trimetazidine, ischemic heart disease, chronic heart failure, myocardial infarction.

Adabiyotlar

1. Агабабян ИР, Исмаилов ЖА, Рузиева АА. Хроническая сердечная недостаточность у молодых пациентов с ожирением на фоне хронической обструктивной болезни легких. Достижения науки и образования. 2020(3 (57)). 2. Агабабян ИР, Садыкова ШШ, Рузиева АА. Оценка состояния больных, перенесших инфаркт миокарда, осложненный хронической сердечной недостаточностью на фоне приема кардиопротекторов. Достижения науки и образования. 2020(3(75)). 3. Беленков Ю.Н., Мареев В.Ю. Принципы рационального лечения сердечной недостаточности. - М.: Медиа Медика, 2018. - 266 с. 4. Васюк Ю.А., Хаджеганова А.Б., Ющук Е.Н. и др. Гибернирующий миокард и процессы постин-фарктного ремоделирования левого желудочка // Сердечная недостаточность. 2016; 2(4): 180-186. 5. Флоря В.Г., Мареев В.Ю., Самко А.Н. и др. Ремоделирование левого желудочка у пациентов с первичным поражением миокарда // Кардиология. 2017; 37(2): 10-15. 6. Fabiani J.N., Ponzio О., Emerit I. et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery //J. Cardiovasc. Surg. 2016; 33: 486-491.